Parse Biosciences, a Qiagen company, announced on February 19, 2026 that it has launched Evercode Whole Transcriptome v4, a new chemistry for single‑cell RNA sequencing that delivers a shorter workflow, higher sensitivity, and up to 75 % greater cell recovery. The platform can process up to five million cells and 384 samples in a single run, while reducing sequencing reads and costs through a magnetic‑bead‑based workflow that replaces centrifugation steps.
The new chemistry uses split‑pool combinatorial barcoding to achieve a higher gene‑detection rate per cell, enabling researchers to generate larger, higher‑quality datasets with fewer sequencing reads. The instrument‑free design and simplified workflow lower hands‑on time and reduce consumable usage, making the technology more accessible to laboratories that previously relied on more complex single‑cell platforms.
Qiagen’s acquisition of Parse in November 2025 for $225 million upfront plus milestone payments was intended to broaden its Sample Technologies portfolio and accelerate its entry into the rapidly expanding single‑cell market. The launch of Evercode v4 is a key milestone in that strategy, positioning Qiagen to compete with leaders such as 10x Genomics while providing a scalable, cost‑effective solution that supports AI‑driven drug discovery and personalized medicine.
"Evercode v4 reflects years of work and direct feedback from customers, delivering a leap forward in cell recovery and sensitivity combined with a simpler workflow," said Charlie Roco, PhD, co‑founder and chief technology officer of Parse Biosciences. "Our goal from the beginning was to provide the research community with single‑cell technology that is scalable, accessible, and high‑performing." Thierry Bernard, CEO of Qiagen, added, "The addition of the Parse team to QIAGEN will significantly strengthen our offerings in one of the most dynamic areas of life science." He further noted, "Single‑cell analysis is the key to understanding health and disease at a mechanistic level. By combining Parse with our Sample technologies portfolio and QDI bioinformatics offering, we can provide researchers with the tools to generate the massive datasets required to build predictive virtual cell models that fuel AI‑based drug discovery."
The product is slated to begin shipping in March 2026 and is expected to contribute approximately $40 million in sales to Qiagen in 2026, with the acquisition projected to be dilutive to adjusted EPS by about $0.04 that year. The launch underscores Qiagen’s commitment to expanding its high‑performance, scalable solutions for the single‑cell market and to supporting the growing demand for AI‑enabled biological data.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.